MDxHealth (MDXH) Stock Price, News & Analysis

Company Overview

MDxHealth SA is a molecular diagnostics company focused on precision testing for urologic diseases, particularly prostate cancer. The company develops and commercializes tests that use genomic and epigenetic information to help physicians assess disease risk, guide biopsy and treatment decisions, and monitor patients.

Its principal products include ConfirmMDx, a tissue-based test designed to identify molecular changes associated with occult prostate cancer in men whose biopsy results are negative; and SelectMDx, a noninvasive urine test intended to help assess the risk of clinically significant prostate cancer in men with an elevated prostate-specific antigen level or other concerning findings. MDxHealth also offers ResolveMDx, a molecular test used in the evaluation of urinary tract infections and related treatment considerations.

MDxHealth was established in Belgium and has expanded its operations in the United States, where it maintains a significant commercial and laboratory presence, while continuing to serve healthcare providers and patients in European and other international markets. Its tests are marketed through relationships with urologists, health systems, laboratories, and other healthcare organizations. The company is led by Chief Executive Officer Michael McGarrity.

Key Stats

• Today's Range: $0.56 to $0.60
• 50-Day Range: $0.40 to $0.86
• 52-Week Range: $0.40 to $5.33
• Volume: 222,589 shs
• Average Volume: 215,469 shs
• Market Capitalization: $28.81 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $2.17
• Consensus Rating: Hold

MDxHealth Stock Analysis - MarketRank™

MDxHealth scored higher than 44% of companies evaluated by MarketBeat, and ranked 607th out of 901 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Hold

Consensus Rating

MDxHealth has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

MDxHealth has a consensus price target of $2.17, representing about 272.3% upside from its current price of $0.58.

Amount of Analyst Coverage

MDxHealth has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for MDxHealth are expected to grow in the coming year, from ($0.49) to ($0.32) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of MDxHealth is -0.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of MDxHealth is -0.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.12% of the float of MDxHealth has been sold short.

Short Interest Ratio / Days to Cover

MDxHealth has a short interest ratio ("days to cover") of 7.79.

Change versus previous month

Short interest in MDxHealth has recently decreased by 1.13%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

MDxHealth does not currently pay a dividend.

Dividend Growth

MDxHealth does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for MDxHealth this week, compared to 2 articles on an average week.

Search Interest

7 people have searched for MDXH on MarketBeat in the last 30 days. This is an increase of 75% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added MDxHealth to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, MDxHealth insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.70% of the stock of MDxHealth is held by insiders.

Percentage Held by Institutions

MDxHealth has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 9/24/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:MDXH
• CIK: 1872529
• Web: mdxhealth.com
• Phone: 324-364-2070
• Fax: 32042597875
• Employees: 364
• Year Founded: 2003

Price Target and Rating

• Average Price Target for MDxHealth: $2.17
• High Price Target: $3.00
• Low Price Target: $1.50
• Potential Upside/Downside: +272.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.40
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.72)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$33.52 million
• Net Margins: -33.46%
• Pretax Margin: -32.79%
• Return on Equity: N/A
• Return on Assets: -24.25%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.15
• Quick Ratio: 0.98

Sales & Book Value

• Annual Sales: $107.88 million
• Price / Sales: 0.27
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.24) per share
• Price / Book: -2.43

Miscellaneous

• Outstanding Shares: 49,500,000
• Free Float: 48,656,000
• Market Cap: $28.81 million
• Optionable: Not Optionable
• Beta: 1.57